Novo Nordisk A/S (NYSE:NVO) Stock Price Up 5.1% Following Analyst Upgrade

Novo Nordisk A/S (NYSE:NVO)’s share price rose 5.1% during mid-day trading on Wednesday after Morgan Stanley upgraded the stock from an underweight rating to an equal weight rating. Morgan Stanley now has a $40.00 price target on the stock. Novo Nordisk A/S traded as high as $38.60 and last traded at $38.53. Approximately 26,442,539 shares traded hands during mid-day trading, a decline of 2% from the average daily volume of 27,024,658 shares. The stock had previously closed at $36.66.

A number of other research firms have also recently weighed in on NVO. Zacks Research cut Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, February 9th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Finally, CICC Research started coverage on shares of Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 price target for the company. Five analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $53.93.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley upgraded NVO to Equal-weight, saying the recent sell-off better prices mid‑term risks and setting a $40 price target — this reduced perceived downside and likely helped buying interest. Morgan Stanley upgrades Novo Nordisk, says risks better priced after sell-off
• Positive Sentiment: Investors reacted to FDA moves against telehealth GLP‑1 advertisers as potentially removing low‑quality/rogue competition and stabilizing branded channel economics for incumbents like Novo. Novo Nordisk (NVO) Stock Jumps 3% as FDA Cracks Down on Telehealth GLP-1 Advertisers
• Positive Sentiment: Company is investing heavily in production capacity (Ireland facility upgrades and a Monksland expansion) to secure supply for Wegovy and oral formulations — positive for long‑term market defense. Novo Nordisk Announces $372.5M Expansion in Monksland, Athlone, Ireland
• Neutral Sentiment: Market debate on valuation and whether current pricing reflects too much pessimism continues; some pieces argue downside is priced while others flag remaining execution/competitive risks. Is Novo Nordisk (NYSE:NVO) Now Pricing In Too Much Pessimism After Share Price Slump
• Neutral Sentiment: Roche and other rivals are explicitly targeting the obesity market — a longer‑term competitive factor investors are watching but not an immediate earnings shock. Roche targets double-digit market share in weight loss, aims to catch up with Novo
• Negative Sentiment: The FDA issued a second warning ordering Novo to stop a consumer Ozempic ad for being misleading — immediate regulatory/marketing headwind and reputational risk. US FDA warns Novo for second time about misleading Ozempic advertising
• Negative Sentiment: Pomerantz has opened an investor investigation into Novo — potential litigation risk that can weigh on sentiment if it escalates. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO
• Negative Sentiment: Planned halving of Wegovy’s US list price in 2027 signals pricing pressure and margin risk for the obesity franchise (volume vs. price trade‑off). Novo Nordisk to halve US list price of Wegovy in 2027
• Negative Sentiment: The American Hospital Association urged HRSA to stop Novo’s new claims‑data submission policy affecting 340B hospitals, adding regulatory and stakeholder friction. AHA urges HRSA to stop Novo Nordisk’s new claims-data submission policy on 340B hospitals from going into effect
• Negative Sentiment: Generic/biosimilar Ozempic competition is progressing (Canada generic anticipated), a potential revenue headwind in affected markets. Aspen expects Canada nod for generic targeting Novo’s Ozempic by September

Institutional Trading of Novo Nordisk A/S

Large investors have recently modified their holdings of the company. Quotient Wealth Partners LLC raised its position in shares of Novo Nordisk A/S by 2.0% during the 4th quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock worth $463,000 after buying an additional 177 shares in the last quarter. Certuity LLC increased its position in Novo Nordisk A/S by 3.6% in the 4th quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after purchasing an additional 177 shares during the last quarter. Beacon Financial Group raised its holdings in shares of Novo Nordisk A/S by 4.3% during the 3rd quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock valued at $239,000 after purchasing an additional 178 shares in the last quarter. Oakworth Capital Inc. lifted its position in shares of Novo Nordisk A/S by 41.6% in the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock worth $31,000 after buying an additional 182 shares during the last quarter. Finally, True North Advisors LLC boosted its position in Novo Nordisk A/S by 3.9% during the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock worth $270,000 after purchasing an additional 199 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 5.1%

The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The business’s 50 day moving average is $52.24 and its 200-day moving average is $52.68. The firm has a market capitalization of $172.04 billion, a price-to-earnings ratio of 11.10 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The company also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be issued a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is 23.63%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.